Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38648580/
Although sNfL correlated with the presence of Gd+ lesions, most participants with Gd+ lesions did not have elevations in sNfL levels. These observations have implications for the use and interpretation...
In the RESTORE trial, serum neurofilament light chain (sNfL) levels correlated with gadolinium-enhancing lesions in MS, but most patients with lesions showed no significant sNfL elevation, complicating its use as a biomarker.
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38469809/
NCT00027300URL: https://clinicaltrials.gov/ct2/show/NCT00027300.
Natalizumab significantly reduces gray matter and thalamic atrophy in relapsing-remitting multiple sclerosis patients, with 64.3% less gray matter loss and 57.0% less thalamic volume loss compared to placebo.
MS treatment de-escalation: review and commentary - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39093335/
Almost all currently licensed disease-modifying therapies (DMTs) for MS treatment require prolonged if not lifelong administration. Yet, as people age, the immune system has increasingly reduced responsiveness, known as immunosenescence....
De-escalation of MS disease-modifying therapies in older patients may maintain efficacy while reducing risks, but larger, longer studies are needed to confirm safety and effectiveness across age groups.
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38032059/
We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there...
This study compared adverse effects of multiple sclerosis immunotherapies through network meta-analyses, highlighting varying safety profiles, with low-certainty evidence for drug rankings and significant withdrawal rates due to adverse events.
Bioavailable central nervous system disease-modifying therapies for multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38162670/
Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous...
Disease-modifying therapies for relapsing multiple sclerosis primarily target peripheral immune cells, while cladribine and sphingosine 1-phosphate receptor modulators show potential for direct effects on the central nervous system.